Research Projects

Selected publicly and/or privately funded R&D projects with active involvement of Fraunhofer MEVIS.

STIMULATE

01/2015 - 12/2019

The Magdeburg Forschungscampus STIMULATE is a project within the initiative "Forschungscampus – Public-Private Partnership to Foster Innovation" funded by the BMBF. The focus of STIMULATE are technologies for image-guided minimally invasive methods in medicine. The aim is to improve medical treatments as well as to help contain of exploding health care costs. In particular, age-related common diseases in the areas of oncology, neurology and vascular diseases are considered. In the long term, the project aims to become the "German Centre for Image-guided Medicine".

Main funding: BMBF
Role of MEVIS: consortium member

STIMULATE

TRANS-FUSIMO

01/2014 - 12/2018

Logo Trans-Fusimo Project
© Photo Fraunhofer-Gesellschaft

TRANS-FUSIMO is an EU funded project involving 11 partners from all over Europe. The project is a follow up project of FUSIMO where a planning system for MR-guided Focused Ultrasound Surgery (MRgFUS) in moving abdominal organs has been devoloped. MRgFUS combines high intensity focused ultrasound for thermal ablation of diseased tissue with MR imaging to visualise the tumour and surrounding anatomy and to provide MR thermal feedback. However, MRgFUS treatment of the liver and other abdominal organs present tremendous technological challenges, including motion due to breathing and shielding of the target by the rib cage. Thus, TRANS-FUSIMO will translate MRgFUS in the liver to the clinic.

Main funding: EC
Role of MEVIS: consortium leader, scientific coordinator

TRANS-FUSIMO

German National Cohorte

06/2013 - 04/2018

Logo National Cohort Project
© Photo NATIONALE KOHORTE e.V.

The German National Cohort (GNC) is a joint interdisciplinary endeavour of scientists from the Helmholtz and the Leibniz Association, universities, and other research institutes. Its aim is to investigate the causes for the development of major chronic diseases, i.e. cardiovascular diseases, cancer, diabetes, neurodegenerative/-psychiatric diseases, musculoskeletal diseases, respiratory and infectious diseases, and their pre-clinical stages or functional health impairments. Across Germany, a random sample of the general population will be drawn by 18 regional study centres, including a total of 100,000 women and 100,000 men aged 20–69 years.

Main funding: BMBF
Role of MEVIS: consortium member

Nationale Kohorte (NAKO)

WAKE-UP

12/2011 - 11/2016

Logo Wake-Up Stroke Project
© Photo WAKE-UP

WAKE-UP is a European multicentre investigator-initiated randomized placebo-controlled clinical trial of MRI based thrombolysis in acute stroke patients with unknown time of symptom onset, e.g. due to recognition of stroke symptoms on awakening. The objective of WAKE-UP is to test efficacy and safety of MRI-based intravenous thrombolysis with Alteplase in patients waking up with stroke symptoms or patients with unknown symptom onset. By this, WAKE-UP aims at providing a new safe and effective treatment option for acute stroke patients waking up with stroke symptoms.

Main funding: EC
Role of MEVIS: consortium member

WAKE-UP

CARDIOPROOF

10/2013 - 09/2016

Logo Cardioproof
© Photo Cardioproof

CARDIOPROOF is a project to determine the applicability and effectiveness of predictive modelling and simulation tools for cardiology. Consolidating the outcomes of previous Virtual Physiological Human (VPH) projects, CARDIOPROOF will validate the tools in interrelated clinical trials. These trials will be conducted at three European centres of excellence in cardiac treatment: The Ospedale Pediatrico Bambin Gesù, in Rome; University College of London’s Great Ormond Street Hospital for Children NHS Foundation Trust (GOSH); and the Deutsches Herzzentrum Hospital of Berlin.

Main funding: EC
Role of MEVIS: consortium member

CARDIOPROOF

 

 

SPARTA

04/2013 - 07/2016

Logo Sparta Project
© Photo Fraunhofer-Gesellschaft

Alongside surgery and chemotherapy, radiation therapy is one of the pillars of treatment of malignant tumors. Precisely targeting the tumor and sparing the surrounding healthy tissue are important prerequisites for therapeutic success. The SPARTA consortium is developing software to improve therapy planning and optimize patient-specific treatment. Scientists from ten partners, including research institutes, medical technology companies, and university clinics, develop innovative, adaptive, and expandable software systems to help clinicians plan and perform radiation therapy. SPARTA’s overarching aim is to increase the safety and efficiency of radiation, and support tumor radiation in a more patient-friendly manner using innovative systems.

Main funding: BMBF
Role of MEVIS: consortium leader, scientific coordinator

SPARTA

VPH-PRISM

03/2013 - 02/2016

Logo VPH-Prism Project
© Photo European Institute for Biomedical Imaging Research gemeinnützige GmbH

Breast cancer is frequent and life threatening, but curable if detected early. Early detection and comprehensive characterisation of findings require optimised imaging and image understanding to maximise detection of significant disease while preventing overdiagnosis. Personalised predictive modeling of breast cancer allows treatment stratification, preventing unnecessary and unsuccessful treatments. VPH-PRISM addresses these key topics with integrated multidisciplinary, multi-scale ICT modeling of breast tissue microstructure in the context of environmental, genetic, and clinical factors.

Main funding: EC
Role of MEVIS: consortium leader, scientific coordinator

VPH-PRISM

Virtual Liver Network

04/2010 - 03/2015

Logo Virtual Liver Network Project
© Photo Virtual Liver Network

The Virtual Liver Network (VLN) represents a major research investment by the German Government focusing on work at the “bleeding edge” of Systems Biology and Systems Medicine. This Flagship Programme is tackling one of the major challenges in the life sciences: that is, how to integrate the wealth of data we have acquired post-genome, not just in a mathematical model, but more importantly in a series of models that are linked across scales to represent organ function. As the project is prototyping how to achieve true multi-scale modelling within a single organ and linking this to human physiology, it will be developing tools and protocols that can be applied to other systems, helping to drive forward the application of modelling and simulation to modern medical practice. While there is no direct successor for the Virtual Liver network, there is LiSyM, a large scale Liver Systems Medicine project, funded by the BMBF since beginning of 2016.

Main funding: BMBF
Role of MEVIS: consortium member, subproject leader

Virtual Liver Network